首页 > 最新文献

Journal of Renal Nutrition最新文献

英文 中文
Comparison Between Global Leadership Initiative on Malnutrition Criteria and Protein-Energy Wasting in Patients With Kidney Failure Undergoing Peritoneal Dialysis 腹膜透析肾衰竭患者营养不良标准和蛋白质能量消耗全球领导倡议的比较。
IF 3.2 3区 医学 Q2 NUTRITION & DIETETICS Pub Date : 2025-09-01 DOI: 10.1053/j.jrn.2025.01.006
Gabriela Leal-Escobar MNA , Annabel Biruete PhD , Karla Berenice Cano-Escobar MD , Magdalena Madero MD , Ivan Armando Osuna-Padilla PhD

Objective

Protein-energy wasting (PEW) is the chronic kidney disease-specific diagnosis encompassing malnutrition. PEW is associated with adverse outcomes, including those receiving peritoneal dialysis (PD). Identifying PEW requires accurate methods to improve diagnosis. The Global Leadership Initiative on Malnutrition (GLIM) criteria is focused on validating a global consensus for malnutrition diagnosis in adults in clinical settings. While the GLIM criteria has been extensively studied in other clinical populations, there is limited evidence about the agreement with PEW in the PD setting. The aim of this study was to assess the agreement, accuracy, sensitivity, and specificity of GLIM criteria in comparison to the malnutrition inflammation score (MIS), a widely used tool to diagnose PEW in patients on dialysis.

Methods

This was a cross-sectional study of patients undergoing PD. PEW was diagnosed using MIS score. Nutritional assessment was performed to identify malnutrition using GLIM criteria. Phenotypic criteria were assessed using low body mass index, low fat-free mass index, or low muscle strength. Etiology criteria were evaluated using high serum C-reactive protein or reduced food intake. The concordance between GLIM and MIS was evaluated by the Kappa test. A receiver operating characteristic curve was used for identifying area under curve, sensitivity, and specificity of GLIM.

Results

Patients undergoing PD (n = 154) were included in the study. Participants had a median age of 40 (29-51) years and 46.7% were male. PEW/malnutrition was diagnosed using MIS score in 35.3% and in 27.3% using the GLIM criteria. In comparison with MIS (used as the diagnostic reference), the sensitivity of GLIM was 65.8%, specificity 61.6%, and area under curve was 0.63. The weighted Kappa coefficient was (k 0.15, P = .02.).

Conclusion

GLIM criteria did not perform better than MIS in diagnosing PEW/malnutrition in patients in PD. Future research to assess the association of GLIM criteria with clinical outcomes is needed.
背景:蛋白质能量消耗(PEW)是慢性肾脏疾病(CKD)的特异性诊断,包括营养不良。PEW与不良结果相关,包括接受腹膜透析(PD)的患者。识别PEW需要准确的方法来提高诊断。全球营养不良领导倡议(GLIM)标准的重点是验证临床环境中成人营养不良诊断的全球共识。虽然GLIM标准在其他临床人群中得到了广泛的研究,但在PD设置中,与PEW一致的证据有限。本研究的目的是评估GLIM标准与营养不良炎症评分(MIS)的一致性、准确性、敏感性和特异性,MIS是一种广泛用于诊断透析患者皮尤的工具。方法:这是一项对PD患者的横断面研究。皮尤诊断使用MIS评分。采用GLIM标准进行营养评估以确定营养不良。表型标准通过低身体质量指数、低无脂质量指数或低肌肉力量进行评估。采用高血清c反应蛋白或减少食物摄入量来评估病因标准。采用Kappa检验评价GLIM与MIS的一致性。采用roc曲线鉴定GLIM的曲线下面积(AUC)、敏感性和特异性。结果:接受PD治疗的患者(n=154)被纳入研究。参与者的中位年龄为40岁(29-51岁),46.7%为男性。使用MIS评分诊断为PEW/营养不良的比例为35.3%,使用GLIM标准诊断为27.3%。与MIS(作为诊断参考)相比,GLIM的敏感性为65.8%,特异性为61.6%,AUC为0.63。加权Kappa系数为(k0.15, p=0.02)。结论:GLIM标准在诊断PD患者的皮尤/营养不良方面并不优于MIS标准。未来的研究需要评估GLIM标准与临床结果的关系。
{"title":"Comparison Between Global Leadership Initiative on Malnutrition Criteria and Protein-Energy Wasting in Patients With Kidney Failure Undergoing Peritoneal Dialysis","authors":"Gabriela Leal-Escobar MNA ,&nbsp;Annabel Biruete PhD ,&nbsp;Karla Berenice Cano-Escobar MD ,&nbsp;Magdalena Madero MD ,&nbsp;Ivan Armando Osuna-Padilla PhD","doi":"10.1053/j.jrn.2025.01.006","DOIUrl":"10.1053/j.jrn.2025.01.006","url":null,"abstract":"<div><h3>Objective</h3><div>Protein-energy wasting (PEW) is the chronic kidney disease-specific diagnosis encompassing malnutrition. PEW is associated with adverse outcomes<span>, including those receiving peritoneal dialysis (PD). Identifying PEW requires accurate methods to improve diagnosis. The Global Leadership Initiative on Malnutrition (GLIM) criteria is focused on validating a global consensus for malnutrition diagnosis in adults in clinical settings. While the GLIM criteria has been extensively studied in other clinical populations, there is limited evidence about the agreement with PEW in the PD setting. The aim of this study was to assess the agreement, accuracy, sensitivity, and specificity of GLIM criteria in comparison to the malnutrition inflammation score (MIS), a widely used tool to diagnose PEW in patients on dialysis.</span></div></div><div><h3>Methods</h3><div>This was a cross-sectional study of patients undergoing PD. PEW was diagnosed using MIS score. Nutritional assessment<span> was performed to identify malnutrition using GLIM criteria. Phenotypic criteria were assessed using low body mass index, low fat-free mass index, or low muscle strength. Etiology criteria were evaluated using high serum C-reactive protein or reduced food intake. The concordance between GLIM and MIS was evaluated by the Kappa test. A receiver operating characteristic curve was used for identifying area under curve, sensitivity, and specificity of GLIM.</span></div></div><div><h3>Results</h3><div><span>Patients undergoing PD (n = 154) were included in the study. Participants had a median age of 40 (29-51) years and 46.7% were male. PEW/malnutrition was diagnosed using MIS score in 35.3% and in 27.3% using the GLIM criteria. In comparison with MIS (used as the diagnostic reference), the sensitivity of GLIM was 65.8%, specificity 61.6%, and area under curve was 0.63. The weighted Kappa coefficient was (k 0.15, </span><em>P</em> = .02.).</div></div><div><h3>Conclusion</h3><div>GLIM criteria did not perform better than MIS in diagnosing PEW/malnutrition in patients in PD. Future research to assess the association of GLIM criteria with clinical outcomes is needed.</div></div>","PeriodicalId":50066,"journal":{"name":"Journal of Renal Nutrition","volume":"35 5","pages":"Pages 682-689"},"PeriodicalIF":3.2,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143069215","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Correlation of Nutritional Risk Indicators and Cognitive Function on Mexican Hemodialysis Patients: Cross-Sectional Study 墨西哥血液透析患者营养风险指标与认知功能的相关性:横断面研究。
IF 3.2 3区 医学 Q2 NUTRITION & DIETETICS Pub Date : 2025-09-01 DOI: 10.1053/j.jrn.2025.04.006
García-Cruz María Fernanda MSc , Rios-Rios Brenda Daniela MSc , Cárdenas Yolitzy PhD , Ríos-Silva Mónica PhD , Trujillo Xóchitl PhD , Huerta Miguel PhD , Bermúdez-Aceves Luis Antonio MD , Sánchez-Meza Karmina PhD , Bricio-Barrios Jaime Alberto PhD

Objective

Deterioration of cognitive status and malnutrition are very common in patients with hemodialysis; these patients usually have a greater decline in their cognitive performance than individuals of the same age in the general population. The objective of the study was to correlate cognitive function with nutritional risk indicators in adults receiving hemodialysis treatment in the state of Colima, Mexico.

Methods

Analytical, cross-sectional study, which included 63 people (aged >18 years) of both sexes, who attended the Colima State Hemodialysis Center. Each patient who agreed to participate signed an informed consent. Nutritional risk was measured with the Nutritional Control Scale. To evaluate cognitive status, the Brief Neuropsychological Test in Spanish was used.

Results

Overall, 38.1% of the participants were women and 61.9% were men, with a median age of 52 (interquartile range 24.5) years. In addition, 58.7% of the participants presented cognitive impairment, and 14.3% were at nutritional risk. Albumin presented a positive correlation with the recall and encoding domains, the latter being stronger in the group of patients with moderate to severe nutritional risk, and lymphocytes were strongly and negatively correlated with the encoding domain.

Conclusion

No association was found between cognitive status and nutritional status in this study. However, a positive correlation of albumin and lymphocytes with some domains of cognitive function was found, especially in patients with nutritional risk.
导读:血液透析患者认知状况恶化和营养不良十分常见;这些患者的认知能力通常比一般人群中同龄的人下降得更大。目的:该研究的目的是在墨西哥XXXX州接受血液透析治疗的成年人中,将认知功能与营养风险指标联系起来。方法:分析性横断面研究,纳入63名在XXX州立血液透析中心就诊的男女患者(18岁~ 18岁)。每位同意参与的患者都签署了知情同意书。采用营养控制量表(CONUT)测量营养风险。为了评估认知状态,使用了西班牙语简短神经心理测试(NEUROPSI)。结果:38.1%的参与者为女性,61.9%为男性,中位年龄为52岁(IQR 24.5)岁。58.7%的参与者表现出认知障碍,14.3%的人有营养风险。白蛋白与回忆域和编码域呈正相关,后者在中度至重度营养风险患者组中更强,淋巴细胞与编码域呈强负相关。结论:本研究未发现认知状况与营养状况之间存在关联。然而,白蛋白和淋巴细胞与某些认知功能领域呈正相关,特别是在有营养风险的患者中。
{"title":"Correlation of Nutritional Risk Indicators and Cognitive Function on Mexican Hemodialysis Patients: Cross-Sectional Study","authors":"García-Cruz María Fernanda MSc ,&nbsp;Rios-Rios Brenda Daniela MSc ,&nbsp;Cárdenas Yolitzy PhD ,&nbsp;Ríos-Silva Mónica PhD ,&nbsp;Trujillo Xóchitl PhD ,&nbsp;Huerta Miguel PhD ,&nbsp;Bermúdez-Aceves Luis Antonio MD ,&nbsp;Sánchez-Meza Karmina PhD ,&nbsp;Bricio-Barrios Jaime Alberto PhD","doi":"10.1053/j.jrn.2025.04.006","DOIUrl":"10.1053/j.jrn.2025.04.006","url":null,"abstract":"<div><h3>Objective</h3><div>Deterioration of cognitive status and malnutrition are very common in patients with hemodialysis<span>; these patients usually have a greater decline in their cognitive performance than individuals of the same age in the general population. The objective of the study was to correlate cognitive function with nutritional risk indicators in adults receiving hemodialysis treatment in the state of Colima, Mexico.</span></div></div><div><h3>Methods</h3><div><span>Analytical, cross-sectional study, which included 63 people (aged &gt;18 years) of both sexes, who attended the Colima State Hemodialysis Center. Each patient who agreed to participate signed an informed consent. Nutritional risk was measured with the Nutritional Control Scale. To evaluate cognitive status, the Brief </span>Neuropsychological Test in Spanish was used.</div></div><div><h3>Results</h3><div>Overall, 38.1% of the participants were women and 61.9% were men, with a median age of 52 (interquartile range 24.5) years. In addition, 58.7% of the participants presented cognitive impairment, and 14.3% were at nutritional risk. Albumin presented a positive correlation with the recall and encoding domains, the latter being stronger in the group of patients with moderate to severe nutritional risk, and lymphocytes were strongly and negatively correlated with the encoding domain.</div></div><div><h3>Conclusion</h3><div>No association was found between cognitive status and nutritional status in this study. However, a positive correlation of albumin and lymphocytes with some domains of cognitive function was found, especially in patients with nutritional risk.</div></div>","PeriodicalId":50066,"journal":{"name":"Journal of Renal Nutrition","volume":"35 5","pages":"Pages 663-671"},"PeriodicalIF":3.2,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144044769","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Declining Serum Albumin With Stable Body Mass Index: A Mortality Indicator in Predialysis Chronic Kidney Disease 血清白蛋白下降与BMI稳定:透析前CKD的死亡率指标。
IF 3.2 3区 医学 Q2 NUTRITION & DIETETICS Pub Date : 2025-09-01 DOI: 10.1053/j.jrn.2025.04.005
Menaka Sarav MD , Prabin Shrestha MD , Adnan Naseer MD , Fridtjof Thomas PhD , Keiichi Sumida MD, MPH, PhD, FASN , Kamyar Kalantar-Zadeh MD, MPH, PhD , Csaba P. Kovesdy MD

Objective

This study aimed to investigate changes in nutritional markers in patients with predialysis chronic kidney disease (CKD) and stable body mass index (BMI).

Methods

We analyzed data from a nationwide cohort of US Veterans with advanced CKD who transitioned to kidney replacement therapy from October 1, 2007, through March 31, 2015. We identified 20,164 U.S. veterans with stable BMI and multiple serum albumin measurements. We calculated intraindividual slopes of serum albumin using mixed effects models for 3 years preceding dialysis. We examined the association of serum albumin slope with mortality after dialysis initiation using Cox proportional hazards models adjusted for demographic characteristics, comorbidities, and baseline estimated glomerular filtration rate and serum albumin.

Results

The cohort had a mean age of 64 years, with 98.3% male and 30% African American participants. Despite maintaining stable BMI, 81% of patients displayed a decline in serum albumin levels in the predialysis period (median slope: −0.09 g/dL/year, 25th and 75th percentile: −0.17, −0.02). A steeper decline in serum albumin over time was associated with significantly higher postdialysis mortality (multivariable-adjusted hazard ratio associated with −1 g/dL/year decline in serum albumin: 1.86, 95% confidence interval: 1.65-2.10, P < .001).

Conclusion

A large proportion of patients with advanced CKD display a clinically relevant decline in serum albumin despite maintaining a stable BMI. Our study highlights the limitations of stable BMI as a marker of nutritional adequacy in advanced CKD, emphasizing the need for more comprehensive nutritional assessments in CKD management.
目的:探讨透析前慢性肾病(CKD)患者营养指标及稳定体重指数(BMI)的变化。方法:我们分析了2007年10月1日至2015年3月31日期间过渡到肾脏替代治疗的美国晚期CKD退伍军人的全国队列数据。我们确定了20164名美国退伍军人,他们有稳定的BMI和多种血清白蛋白测量。我们使用混合效应模型计算了透析前三年个体内血清白蛋白的斜率。我们检查了透析开始后血清白蛋白斜率与死亡率的关系,使用Cox比例风险模型调整了人口统计学特征、合并症、基线eGFR和血清白蛋白。结果:该队列的平均年龄为64岁,其中98.3%为男性,30%为非洲裔美国人。尽管保持稳定的BMI, 81%的患者在透析前表现出血清白蛋白水平下降(斜率中位数:-0.09 g/dl/年,第25和75百分位:-0.17,-0.02)。随着时间的推移,血清白蛋白急剧下降与透析后死亡率显著升高相关(血清白蛋白-1 g/dl/年下降相关的多变量调整风险比:1.86,95%可信区间:1.65-2.10)。结论:很大比例的晚期CKD患者尽管保持稳定的BMI,但血清白蛋白仍表现出临床相关的下降。我们的研究强调了稳定的BMI作为晚期CKD营养充足的标志的局限性,强调了在CKD管理中需要更全面的营养评估。索引词:慢性肾脏疾病(CKD),血清白蛋白,蛋白质能量消耗(PEW),营养评估,透析后死亡率。
{"title":"Declining Serum Albumin With Stable Body Mass Index: A Mortality Indicator in Predialysis Chronic Kidney Disease","authors":"Menaka Sarav MD ,&nbsp;Prabin Shrestha MD ,&nbsp;Adnan Naseer MD ,&nbsp;Fridtjof Thomas PhD ,&nbsp;Keiichi Sumida MD, MPH, PhD, FASN ,&nbsp;Kamyar Kalantar-Zadeh MD, MPH, PhD ,&nbsp;Csaba P. Kovesdy MD","doi":"10.1053/j.jrn.2025.04.005","DOIUrl":"10.1053/j.jrn.2025.04.005","url":null,"abstract":"<div><h3>Objective</h3><div><span>This study aimed to investigate changes in nutritional markers in patients with predialysis chronic kidney disease (CKD) and stable </span>body mass index (BMI).</div></div><div><h3>Methods</h3><div><span><span>We analyzed data from a nationwide cohort of US Veterans with advanced CKD who transitioned to kidney replacement therapy from October 1, 2007, through March 31, 2015. We identified 20,164 U.S. veterans with stable BMI and multiple </span>serum albumin<span> measurements. We calculated intraindividual slopes of serum albumin<span> using mixed effects models for 3 years preceding dialysis. We examined the association of serum albumin slope with mortality after dialysis initiation using Cox proportional hazards models adjusted for demographic characteristics, comorbidities, and baseline estimated </span></span></span>glomerular filtration rate and serum albumin.</div></div><div><h3>Results</h3><div>The cohort had a mean age of 64 years, with 98.3% male and 30% African American participants. Despite maintaining stable BMI, 81% of patients displayed a decline in serum albumin levels in the predialysis period (median slope: −0.09 g/dL/year, 25th and 75th percentile: −0.17, −0.02). A steeper decline in serum albumin over time was associated with significantly higher postdialysis mortality (multivariable-adjusted hazard ratio associated with −1 g/dL/year decline in serum albumin: 1.86, 95% confidence interval: 1.65-2.10, <em>P</em> &lt; .001).</div></div><div><h3>Conclusion</h3><div>A large proportion of patients with advanced CKD display a clinically relevant decline in serum albumin despite maintaining a stable BMI. Our study highlights the limitations of stable BMI as a marker of nutritional adequacy in advanced CKD, emphasizing the need for more comprehensive nutritional assessments in CKD management.</div></div>","PeriodicalId":50066,"journal":{"name":"Journal of Renal Nutrition","volume":"35 5","pages":"Pages 598-606"},"PeriodicalIF":3.2,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143993899","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
September Meeting Announcements 九月会议公告
IF 3.2 3区 医学 Q2 NUTRITION & DIETETICS Pub Date : 2025-09-01 DOI: 10.1053/j.jrn.2025.07.001
{"title":"September Meeting Announcements","authors":"","doi":"10.1053/j.jrn.2025.07.001","DOIUrl":"10.1053/j.jrn.2025.07.001","url":null,"abstract":"","PeriodicalId":50066,"journal":{"name":"Journal of Renal Nutrition","volume":"35 5","pages":"Page 696"},"PeriodicalIF":3.2,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145109962","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Evaluation and Management of Obesity in Chronic Kidney Disease 慢性肾脏疾病肥胖的评估与管理。
IF 3.2 3区 医学 Q2 NUTRITION & DIETETICS Pub Date : 2025-09-01 DOI: 10.1053/j.jrn.2025.07.004
Allon N. Friedman MD
Obesity is arguably the premier global public health problem of our era. It is also an independent risk factor for the development and progression of chronic kidney disease (CKD) and adverse outcomes in persons with CKD. Fortunately, effective treatment options for obesity have proliferated in just the last few years. These newer therapies in conjunction with older treatments offer great potential in treating obesity and CKD, although many questions remain about their use, efficacy, and place within the overall therapeutic plan. This article will provide a discussion of the definition of obesity, its etiology, and its importance as a risk factor for CKD and other kidney-associated problems. It will then review current treatment options for obesity and the related evidence base. Finally, it will address major topics or controversies that remain unresolved and identify obstacles to effective treatment.
肥胖可以说是我们这个时代首要的全球公共健康问题。它也是慢性肾脏疾病(CKD)发展和CKD患者不良结局的独立危险因素。幸运的是,在过去几年里,针对肥胖的有效治疗方案激增。这些新疗法与旧疗法相结合,在治疗肥胖和慢性肾病方面提供了巨大的潜力,尽管它们的使用、疗效和在整体治疗计划中的位置仍存在许多问题。本文将讨论肥胖的定义,其病因,以及它作为CKD和其他肾脏相关问题的危险因素的重要性。然后,它将审查目前肥胖的治疗方案和相关的证据基础。最后,它将解决仍未解决的主要议题或争议,并确定有效治疗的障碍。
{"title":"Evaluation and Management of Obesity in Chronic Kidney Disease","authors":"Allon N. Friedman MD","doi":"10.1053/j.jrn.2025.07.004","DOIUrl":"10.1053/j.jrn.2025.07.004","url":null,"abstract":"<div><div>Obesity is arguably the premier global public health problem of our era. It is also an independent risk factor for the development and progression of chronic kidney disease (CKD) and adverse outcomes in persons with CKD. Fortunately, effective treatment options for obesity have proliferated in just the last few years. These newer therapies in conjunction with older treatments offer great potential in treating obesity and CKD, although many questions remain about their use, efficacy, and place within the overall therapeutic plan. This article will provide a discussion of the definition of obesity, its etiology, and its importance as a risk factor for CKD and other kidney-associated problems. It will then review current treatment options for obesity and the related evidence base. Finally, it will address major topics or controversies that remain unresolved and identify obstacles to effective treatment.</div></div>","PeriodicalId":50066,"journal":{"name":"Journal of Renal Nutrition","volume":"35 5","pages":"Pages 578-588"},"PeriodicalIF":3.2,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144669280","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Dialysis-Friendly Snack and Sack Lunch Ideas for Skilled Nursing Facilities 为熟练护理机构提供透析友好型零食和便当。
IF 3.2 3区 医学 Q2 NUTRITION & DIETETICS Pub Date : 2025-09-01 DOI: 10.1053/j.jrn.2025.07.008
Melissa Ann Mroz Planells DCN, RDN, CD , Angel Planells MS, RDN
{"title":"Dialysis-Friendly Snack and Sack Lunch Ideas for Skilled Nursing Facilities","authors":"Melissa Ann Mroz Planells DCN, RDN, CD ,&nbsp;Angel Planells MS, RDN","doi":"10.1053/j.jrn.2025.07.008","DOIUrl":"10.1053/j.jrn.2025.07.008","url":null,"abstract":"","PeriodicalId":50066,"journal":{"name":"Journal of Renal Nutrition","volume":"35 5","pages":"Pages e1-e3"},"PeriodicalIF":3.2,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144777681","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Combination of Clinical Frailty Score and Myostatin Concentrations as Mortality Predictor in Hemodialysis Patients 联合临床虚弱评分和肌肉生长抑制素浓度作为血液透析患者死亡率的预测因子。
IF 3.2 3区 医学 Q2 NUTRITION & DIETETICS Pub Date : 2025-09-01 DOI: 10.1053/j.jrn.2025.01.005
Sophie Cornet MD , Kevin Quinonez MD , Xavier Warling MD , François Jouret MD, PhD , Antoine Lanot MD, PhD , Olivier Bruyère PhD , Etienne Cavalier EuSpLM, PhD , Pierre Delanaye MD, PhD

Objectives

Frailty is common among hemodialysis (HD) patients. Its assessment is usually based on clinical criteria. In the present work, we evaluated the interest of combining clinical frailty score and biomarkers to predict mortality of chronic HD patients. Four biomarkers were assessed: myostatin, insulin-like growth factor-1 (IGF-1), dehydroepiandrosterone sulfate (DHEA-S), and serum creatinine-to-cystatin C ratio (SCr/SCys).

Methods

Prevalent HD patients were enrolled from September 2016 to October 2017 in 2 centers in this observational prospective study and followed up for 5 years. Serum levels of myostatin, IGF-1, DHEA-S, and SCr/SCys were measured at baseline. Frailty was assessed using Fried frailty score (≥ 3 indicates frailty). The ability to predict 5-year mortality was assessed by calculating Cox regression analyses and areas under the curve (AUCs).

Results

We included 125 HD patients with the following characteristics: median age of 67 (53; 78) years, 40% of women, 41% of diabetics, and median dialysis vintage of 30 (16; 54) months. Among them, 46% were classified as “Frail” according to Fried score. Mortality rate at 5 years was 56%. The median follow-up was 49 (19; 60) months. Cox univariate analysis showed that higher age, frailty phenotype, and decreased concentrations of myostatin, IGF-1, DHEA-S, and SCr/SCys were associated with higher mortality. In multivariate analysis, only myostatin remained significant among the biomarkers. The AUC of Fried score and myostatin to predict mortality was significant and comparable: 0.72 (95% confidence interval [CI]: 0.63-0.80) and 0.72 (95% CI: 0.64-0.80), respectively. Combining myostatin with Fried score improved significantly the AUC (AUC = 0.79, 95% CI: 0.71-0.86) compared to Fried score alone or myostatin alone (P = .0049 and P = .0035, respectively).

Conclusion

Decreased concentrations of myostatin seem to be independently associated with higher risk of mortality. Combining Fried frailty score with myostatin concentration could improve the prediction of 5-year mortality in chronic HD patients.
背景与目的:虚弱在血液透析(HD)患者中很常见。其评估通常基于临床标准。在目前的工作中,我们评估了结合临床虚弱评分和生物标志物来预测慢性HD患者死亡率的兴趣。评估四项生物标志物:肌肉生长抑制素、胰岛素样生长因子-1 (IGF-1)、硫酸脱氢表雄酮(DHEA-S)和血清肌酐与囊抑素C比值(SCr/SCys)。方法:本观察性前瞻性研究于2016年9月至2017年10月在两个中心招募了流行HD患者,随访5年。在基线时测定血清肌生长抑制素、IGF-1、DHEA-S和SCr/SCys水平。采用Fried衰弱评分(≥3表示虚弱)评估虚弱程度。通过计算Cox回归分析和曲线下面积(AUC)来评估预测5年死亡率的能力。结果:我们纳入125例HD患者,其特征如下:中位年龄67[53;78]岁;40%的女性;41%的糖尿病患者,中位透析时间为30[16;54]个月。其中,46%的人根据弗里德评分被归为“虚弱”。5岁死亡率为56%。中位随访时间为49[19;60]个月。Cox单因素分析显示,较高的年龄、脆弱表型和降低的肌肉生长抑制素、IGF-1、DHEA-S和SCr/SCys浓度与较高的死亡率相关。在多变量分析中,只有肌生长抑制素在生物标志物中保持显著性。Fried评分和肌生长抑制素预测死亡率的AUC具有显著性和可比性:分别为0.72 (95% CI: 0.63至0.80)和0.72 (95% CI: 0.64至0.80)。与单独使用Fried评分或单独使用myostatin相比,联合使用myostatin可显著提高AUC (AUC = 0.79, 95% CI: 0.71 ~ 0.86) (p=0.0049和p=0.0035)。结论:肌生长抑制素浓度降低似乎与较高的死亡风险独立相关。结合Fried衰弱评分和肌生长抑制素浓度可以提高慢性HD患者5年死亡率的预测。
{"title":"Combination of Clinical Frailty Score and Myostatin Concentrations as Mortality Predictor in Hemodialysis Patients","authors":"Sophie Cornet MD ,&nbsp;Kevin Quinonez MD ,&nbsp;Xavier Warling MD ,&nbsp;François Jouret MD, PhD ,&nbsp;Antoine Lanot MD, PhD ,&nbsp;Olivier Bruyère PhD ,&nbsp;Etienne Cavalier EuSpLM, PhD ,&nbsp;Pierre Delanaye MD, PhD","doi":"10.1053/j.jrn.2025.01.005","DOIUrl":"10.1053/j.jrn.2025.01.005","url":null,"abstract":"<div><h3>Objectives</h3><div><span><span>Frailty is common among </span>hemodialysis (HD) patients. Its assessment is usually based on clinical criteria. In the present work, we evaluated the interest of combining clinical frailty score and biomarkers to predict mortality of chronic HD patients. Four biomarkers were assessed: </span>myostatin<span>, insulin-like growth factor-1 (IGF-1), dehydroepiandrosterone sulfate (DHEA-S), and serum creatinine-to-cystatin C ratio (SCr/SCys).</span></div></div><div><h3>Methods</h3><div>Prevalent HD patients were enrolled from September 2016 to October 2017 in 2 centers in this observational prospective study and followed up for 5 years. Serum levels of myostatin<span>, IGF-1, DHEA-S, and SCr/SCys were measured at baseline. Frailty was assessed using Fried frailty score (≥ 3 indicates frailty). The ability to predict 5-year mortality was assessed by calculating Cox regression analyses and areas under the curve (AUCs).</span></div></div><div><h3>Results</h3><div><span><span>We included 125 HD patients with the following characteristics: median age of 67 (53; 78) years, 40% of women, 41% of diabetics, and median dialysis vintage of 30 (16; 54) months. Among them, 46% were classified as “Frail” according to Fried score. Mortality rate at 5 years was 56%. The median follow-up was 49 (19; 60) months. Cox </span>univariate analysis<span><span> showed that higher age, frailty phenotype, and decreased concentrations of myostatin, IGF-1, DHEA-S, and SCr/SCys were associated with higher mortality. In </span>multivariate analysis, only myostatin remained significant among the biomarkers. The AUC of Fried score and myostatin to predict mortality was significant and comparable: 0.72 (95% confidence interval [CI]: 0.63-0.80) and 0.72 (95% CI: 0.64-0.80), respectively. Combining myostatin with Fried score improved significantly the AUC (AUC = 0.79, 95% CI: 0.71-0.86) compared to Fried score alone or myostatin alone (</span></span><em>P =</em> .0049 and <em>P</em> = .0035, respectively).</div></div><div><h3>Conclusion</h3><div>Decreased concentrations of myostatin seem to be independently associated with higher risk of mortality. Combining Fried frailty score with myostatin concentration could improve the prediction of 5-year mortality in chronic HD patients.</div></div>","PeriodicalId":50066,"journal":{"name":"Journal of Renal Nutrition","volume":"35 5","pages":"Pages 636-645"},"PeriodicalIF":3.2,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143054025","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Urine Albumin-creatinine Ratio Accurately Reflects Daily Albuminuria in Nonobese Patients but Requires Body Weight Correction in Obese UACR准确反映非肥胖患者每日蛋白尿,但肥胖患者需要体重矫正。
IF 3.2 3区 医学 Q2 NUTRITION & DIETETICS Pub Date : 2025-09-01 DOI: 10.1053/j.jrn.2025.05.004
Liang-Chun Chen MD , Zih-Kai Kao MS , Chih-Yu Yang MD, PhD , Der-Cherng Tarng MD, PhD

Objective

Urine albumin-creatinine ratio (UACR) is widely used to estimate daily albuminuria. Despite efforts to improve the accuracy of the estimated albumin excretion rate, the individual contributions of age, sex, and body weight remain unexplored.

Methods

This hospital-based cohort study examined the explanatory power of various factors and compared total R2 values across different sets of factors to determine the optimal estimated albumin excretion rate model.

Results

An analysis of 304 24-hour urine samples revealed a median value of 0.538 g (interquartile range: 0.091-2.080 g), identifying UACR and body weight as significant factors with high partial R2 values in estimating daily albuminuria. A novel model using only UACR and body weight demonstrated performance comparable to previous models that included additional variables (total R2 values: ours 0.922 vs. 0.923, P = .893; ours 0.922 vs. 0.925, P = .727), and outperformed the model that excluded body weight (total R2 values: ours 0.922 vs. 0.855, P < .001). Receiver operating characteristic analysis identified 78.1 kg (body mass index [BMI] of 28.5 kg/m2) as the optimal cutoff for predicting underestimation of daily albuminuria by UACR in the heavier half of our patient cohort (area under the curve: 0.865). For individuals with body weight less than 78.1 kg (0th-75.4th percentile), daily albuminuria (g) could be estimated as: 0.033 + 0.999 × UACR (mg/mg) (total R2: 0.966). Conversely, for those weighing ≥78.1 kg (75.5th-100th percentile), the estimation formula was as follows: −3.885 + 1.538 × UACR (mg/mg) + 0.045 × body weight (kg) (total R2: 0.942).

Conclusions

For individuals with a BMI below 28.5 kg/m2, the UACR alone provides sufficient accuracy for estimating daily albuminuria (using the formula: daily albuminuria (g) = 0.033 + 0.999 × UACR (mg/mg)). However, for those with a BMI of 28.5 kg/m2 or higher, adding body weight as a single correction factor to UACR sufficiently improves the explanatory power, simplifying clinical practice by eliminating the need for age and sex as additional factors.
目的:尿白蛋白-肌酐比值(UACR)被广泛用于估算日蛋白尿。尽管努力提高估计白蛋白排泄率(eAER)的准确性,但年龄,性别和体重的个体贡献仍然未被探索。方法:以医院为基础的队列研究,检验各因素的解释能力,比较不同因素组间的总R2值,以确定最佳的eAER模型。结果:304份24小时尿液样本的中位值为0.538 g (IQR: 0.091-2.080 g),确定UACR和体重是估计每日蛋白尿的显著因素,其偏R2值较高。仅使用UACR和体重的新模型表现出与包含其他变量的先前模型相当的性能(总R2值:我们的0.922对0.923,p = 0.893;0.922比0.925,p = 0.727),并且优于排除体重的模型(总R2值:0.922比0.855,p < 0.001)。受试者工作特征分析发现,78.1 kg(体重指数(BMI)为28.5 kg/m2)是我们的患者队列中较重的一半患者UACR预测每日蛋白尿低估的最佳截止值(AUC: 0.865)。对于体重小于78.1 kg(第0 -75.4百分位)的个体,每日蛋白尿(g)可估计为:0.033 + 0.999 × UACR (mg/mg)(总R2: 0.966)。相反,对于体重≥78.1 kg(75.5 -100百分位),估算公式为:-3.885 + 1.538 × UACR (mg/mg) + 0.045 ×体重(kg)(总R2: 0.942)。结论:对于BMI低于28.5 kg/m2的个体,单独使用UACR对估算日蛋白尿有足够的准确性(使用公式:日蛋白尿(g) = 0.033 + 0.999 × UACR (mg/mg))。然而,对于那些BMI为28.5 kg/m2或更高的患者,在UACR中增加体重作为单一校正因素足以提高解释力,通过消除年龄和性别作为附加因素简化临床实践。
{"title":"Urine Albumin-creatinine Ratio Accurately Reflects Daily Albuminuria in Nonobese Patients but Requires Body Weight Correction in Obese","authors":"Liang-Chun Chen MD ,&nbsp;Zih-Kai Kao MS ,&nbsp;Chih-Yu Yang MD, PhD ,&nbsp;Der-Cherng Tarng MD, PhD","doi":"10.1053/j.jrn.2025.05.004","DOIUrl":"10.1053/j.jrn.2025.05.004","url":null,"abstract":"<div><h3>Objective</h3><div>Urine albumin-creatinine ratio (UACR) is widely used to estimate daily albuminuria<span>. Despite efforts to improve the accuracy of the estimated albumin excretion rate, the individual contributions of age, sex, and body weight remain unexplored.</span></div></div><div><h3>Methods</h3><div><span>This hospital-based cohort study examined the explanatory power of various factors and compared total R</span><sup>2</sup> values across different sets of factors to determine the optimal estimated albumin excretion rate model.</div></div><div><h3>Results</h3><div><span>An analysis of 304 24-hour urine samples revealed a median value of 0.538 g (interquartile range: 0.091-2.080 g), identifying UACR and body weight as significant factors with high partial R</span><sup>2</sup><span> values in estimating daily albuminuria<span>. A novel model using only UACR and body weight demonstrated performance comparable to previous models that included additional variables (total R</span></span><sup>2</sup> values: ours 0.922 vs. 0.923, <em>P</em> = .893; ours 0.922 vs. 0.925, <em>P</em> = .727), and outperformed the model that excluded body weight (total R<sup>2</sup> values: ours 0.922 vs. 0.855, <em>P</em> &lt; .001). Receiver operating characteristic analysis identified 78.1 kg (body mass index [BMI] of 28.5 kg/m<sup>2</sup><span>) as the optimal cutoff for predicting underestimation of daily albuminuria<span> by UACR in the heavier half of our patient cohort (area under the curve: 0.865). For individuals with body weight less than 78.1 kg (0th-75.4th percentile), daily albuminuria (g) could be estimated as: 0.033 + 0.999 × UACR (mg/mg) (total R</span></span><sup>2</sup>: 0.966). Conversely, for those weighing ≥78.1 kg (75.5th-100th percentile), the estimation formula was as follows: −3.885 + 1.538 × UACR (mg/mg) + 0.045 × body weight (kg) (total R<sup>2</sup>: 0.942).</div></div><div><h3>Conclusions</h3><div>For individuals with a BMI below 28.5 kg/m<sup>2</sup>, the UACR alone provides sufficient accuracy for estimating daily albuminuria (using the formula: daily albuminuria (g) = 0.033 + 0.999 × UACR (mg/mg)). However, for those with a BMI of 28.5 kg/m<sup>2</sup> or higher, adding body weight as a single correction factor to UACR sufficiently improves the explanatory power, simplifying clinical practice by eliminating the need for age and sex as additional factors.</div></div>","PeriodicalId":50066,"journal":{"name":"Journal of Renal Nutrition","volume":"35 5","pages":"Pages 607-615"},"PeriodicalIF":3.2,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144081798","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Does Protein Intake Have a Significant Impact on eGFR? 蛋白质摄入对eGFR有显著影响吗?
IF 3.2 3区 医学 Q2 NUTRITION & DIETETICS Pub Date : 2025-09-01 DOI: 10.1053/j.jrn.2025.02.009
Ying Guo, Yizhe Xin, Rujia Wang, Bin Fu
{"title":"Does Protein Intake Have a Significant Impact on eGFR?","authors":"Ying Guo,&nbsp;Yizhe Xin,&nbsp;Rujia Wang,&nbsp;Bin Fu","doi":"10.1053/j.jrn.2025.02.009","DOIUrl":"10.1053/j.jrn.2025.02.009","url":null,"abstract":"","PeriodicalId":50066,"journal":{"name":"Journal of Renal Nutrition","volume":"35 5","pages":"Pages 692-693"},"PeriodicalIF":3.2,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144145362","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Serum Phosphate Levels and Mortality in Incident Hemodialysis Patients: A National Retrospective Cohort Study 血清磷酸盐水平与血液透析患者的死亡率:一项全国性回顾性队列研究。
IF 3.2 3区 医学 Q2 NUTRITION & DIETETICS Pub Date : 2025-09-01 DOI: 10.1053/j.jrn.2024.10.003
Mariana Mazzei Caiado Bressan MD , Elisa de Albuquerque Sampaio MD, PhD , Ricardo de Castro Cintra Sesso MD, PhD , Jocemir Ronaldo Lugon MD, PhD

Objectives

Mineral and bone disorders are frequent in patients in hemodialysis (HD) but a definite association of serum phosphate levels with mortality in this population is still an unmet issue. We assessed the association of three phosphate-level ranges with mortality in incident HD patients.

Methods

This national registry-based retrospective cohort study included 6214 incident adult patients on HD for >3 months. Data were collected from January 2011 to December 2018. The serum phosphate levels, represented by the median levels over the course of the entire HD treatment, were stratified into 3 ranges: <3.5 mg/dL, 3.5-5.5 mg/dL, and >5.5 mg/dL. The main outcome was 4-year all-cause mortality.

Results

The frequencies of cases in the lower, intermediate, and higher phosphate ranges were 5.8%, 64.6%, and 29.6%, respectively. In the fully adjusted multivariate model, the higher adopted phosphate range but not the lower one showed a significant association with mortality (hazard ratio [HR]: 1.54, 95% confidence interval [95% CI]: 1.21-1.95, P< .001). In the model, sevelamer, alone (HR: 0.44, 95% CI: 0.32-0.60, P< .001) or in combination with calcium-based phosphate binders (HR: 0.63, 95% CI: 0.40-0.98, P= .041), proved protective. In subgroup analyses, the lower adopted phosphate range was significantly associated with mortality only in patients <60 years. In a sensitivity analysis, we evaluated the effect of incremental intervals of 0.5 mg/dL across the phosphate distribution (from <2.0 mg/dL to ≥8.0 mg/dL), when serum phosphate <2.0 mg/dL was strongly associated with mortality (HR: 21.9, 95% CI: 2.99-160.66, P= .002).

Conclusion

The study reinforced the association of high phosphate levels with mortality in incident HD patients. The use of sevelamer was associated with a lower mortality rate when compared to the use of calcium-based phosphate binders. The lower adopted phosphate range was only associated with mortality in patients <60 years. In a sensitivity analysis though, phosphate levels below 2.0mg/dl were strongly associated with mortality.
目的:矿物质和骨骼疾病在血液透析(HD)患者中很常见,但在这一人群中,血清磷酸盐水平与死亡率的明确关联仍然是一个未解决的问题。我们评估了三种磷酸盐水平范围与HD患者死亡率的关系。方法:这项以全国登记为基础的回顾性队列研究纳入了6214例成年HD患者,患者持续bb103个月。数据收集时间为2011年1月至2018年12月。在整个HD治疗过程中,以中位数水平表示的血清磷酸盐水平分为3个范围:5.5 mg/dL。主要结局为4年全因死亡率。结果:低磷酸盐、中磷酸盐、高磷酸盐发生率分别为5.8%、64.6%、29.6%。在完全调整的多变量模型中,较高的采磷范围与死亡率有显著相关性,而较低的采磷范围与死亡率无显著相关性(风险比[HR]: 1.54, 95%可信区间[95% CI]: 1.21-1.95, P< .001)。在模型中,sevelamer单独使用(HR: 0.44, 95% CI: 0.32-0.60, P< 0.001)或与钙基磷酸盐结合剂联合使用(HR: 0.63, 95% CI: 0.40-0.98, P= 0.041)证明具有保护作用。在亚组分析中,仅在患者中采用较低的磷酸盐水平与死亡率显著相关。结论:该研究强化了高磷酸盐水平与HD患者死亡率的关联。与使用钙基磷酸盐粘合剂相比,sevelamer的使用与较低的死亡率相关。采用较低的磷酸盐范围仅与患者的死亡率有关
{"title":"Serum Phosphate Levels and Mortality in Incident Hemodialysis Patients: A National Retrospective Cohort Study","authors":"Mariana Mazzei Caiado Bressan MD ,&nbsp;Elisa de Albuquerque Sampaio MD, PhD ,&nbsp;Ricardo de Castro Cintra Sesso MD, PhD ,&nbsp;Jocemir Ronaldo Lugon MD, PhD","doi":"10.1053/j.jrn.2024.10.003","DOIUrl":"10.1053/j.jrn.2024.10.003","url":null,"abstract":"<div><h3>Objectives</h3><div>Mineral and bone disorders are frequent in patients in hemodialysis (HD) but a definite association of serum phosphate levels with mortality in this population is still an unmet issue. We assessed the association of three phosphate-level ranges with mortality in incident HD patients.</div></div><div><h3>Methods</h3><div>This national registry-based retrospective cohort study included 6214 incident adult patients on HD for &gt;3 months. Data were collected from January 2011 to December 2018. The serum phosphate levels, represented by the median levels over the course of the entire HD treatment, were stratified into 3 ranges: &lt;3.5 mg/dL, 3.5-5.5 mg/dL, and &gt;5.5 mg/dL. The main outcome was 4-year all-cause mortality.</div></div><div><h3>Results</h3><div>The frequencies of cases in the lower, intermediate, and higher phosphate ranges were 5.8%, 64.6%, and 29.6%, respectively. In the fully adjusted multivariate model, the higher adopted phosphate range but not the lower one showed a significant association with mortality (hazard ratio [HR]: 1.54, 95% confidence interval [95% CI]: 1.21-1.95, <em>P</em>&lt; .001). In the model, sevelamer, alone (HR: 0.44, 95% CI: 0.32-0.60, <em>P</em>&lt; .001) or in combination with calcium-based phosphate binders (HR: 0.63, 95% CI: 0.40-0.98, <em>P</em>= .041), proved protective. In subgroup analyses, the lower adopted phosphate range was significantly associated with mortality only in patients &lt;60 years. In a sensitivity analysis, we evaluated the effect of incremental intervals of 0.5 mg/dL across the phosphate distribution (from &lt;2.0 mg/dL to ≥8.0 mg/dL), when serum phosphate &lt;2.0 mg/dL was strongly associated with mortality (HR: 21.9, 95% CI: 2.99-160.66, <em>P</em>= .002).</div></div><div><h3>Conclusion</h3><div>The study reinforced the association of high phosphate levels with mortality in incident HD patients. The use of sevelamer was associated with a lower mortality rate when compared to the use of calcium-based phosphate binders. The lower adopted phosphate range was only associated with mortality in patients &lt;60 years. In a sensitivity analysis though, phosphate levels below 2.0mg/dl were strongly associated with mortality.</div></div>","PeriodicalId":50066,"journal":{"name":"Journal of Renal Nutrition","volume":"35 5","pages":"Pages 672-681"},"PeriodicalIF":3.2,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142591633","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Journal of Renal Nutrition
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1